The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

December 3, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis. Also, the agency has accepted for priority review a supplemental biologic license application for dupilumab to treat adolescents with atopic dermatitis.

You Might Also Like
  • FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
Explore This Issue
January 2019
Also By This Author
  • Researchers Compare Nonsurgical Knee OA Treatments

Halobetasol Propionate Lotion Approved for Plaque Psoriasis
On Nov. 6, the FDA approved halobetasol propionate lotion (Bryhali) to treat adults with plaque psoriasis for up to eight weeks of use. This lotion is a high-potency corticosteroid (0.01%) in a novel vehicle.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The approval was based on data from two prospective, multicenter, randomized, double-blind clinical trials. During the studies, 430 patients applied halobetasol propionate lotion once daily for eight weeks. The treatment was well tolerated, with no increase in skin atrophy.

The most common adverse reactions occurring in patients treated through Week 8 were: application site dermatitis (1%), hyperglycemia (1%) and upper respiratory tract infection (2%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dupilumab Receives Priority Review
The FDA has accepted the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent) for priority review.2 Dupilumab is a potential treatment for adolescents 12–17 years old with moderate to severe atopic dermatitis whose disease is not adequately controlled by topical therapies or for whom topical treatment is medically unadvisable. At present, no systemic biologic drugs are FDA approved to treat adolescents with moderate to severe atopic dermatitis.

Dupilumab inhibits interleukin 4 (IL-4) and IL-13 signaling, an important contributor to inflammation. The treatment is currently approved for use in adults and as add-on maintenance therapy for patients 12 years and older with two different types of moderate to severe asthma.

In 2016, the FDA granted breakthrough therapy designation for dupilumab for treating moderate to severe atopic dermatitis in adolescents 12–17 years old, as well as severe atopic dermatitis in children 6 months to 11 years old. The target action date for the FDA decision is March 11, 2019.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Ortho Dermatologics. News release: Ortho Dermatologics announces U.S. launch of Bryhali (halobetasol propionate) lotion, 0.01%, for plaque psoriasis in adults. 2018 Nov 7.
  2. Regeneron Pharmaceuticals Inc. News release: FDA grants priority review for Dupixent (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis. 2018 Nov 6.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: dermatitis, dupilumab, FDA, halobetasol propionate lotion, plaque psoriasis, U.S. Food and Drug Administration (FDA)Issue: January 2019

You Might Also Like:
  • FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
  • Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)